Published on
November 23, 2022
- 17:15 GMT
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Updated Phase Ib data on RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndrome (HR-MDS) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting Positive clinical data on RVU120 in …
Distribution channels:
Business & Economy, Technology
...
